• Publications
  • Influence
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
TLDR
Glucagon-like peptide 1 (GLP-1) could be a new treatment for type 2 diabetes, though further investigation of the long-term effects of this peptide hormone is needed. Expand
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
TLDR
The measurement of intact incretin hormones revealed that total as well as intact GIP responses were minimally decreased in patients with type 2 diabetes, whereas the late intact GLP-1 response was strongly reduced, supporting the hypothesis that an impaired function of GLp-1 as a transmitter in the enteroinsular axis contributes to the inappropriate insulin secretion in type 2 diabetic patients. Expand
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
TLDR
It is concluded that the meal-related glucagon-like peptide-1 response in type 1 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes. Expand
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
TLDR
Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes and early nephropathy, and these findings support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in people with conditions that place them at high risk for cardiovascular events. Expand
The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
TLDR
GLP-1 increases insulin secretion in patients with type 2 diabetes and control subjects in a dose-dependent manner and that the beta-cell responsiveness to glucose may be increased to normal levels with a low dose of GLP- 1 infusion. Expand
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
TLDR
It is shown that it is possible to modulate the beta-cell sensitivity to glucose in obese healthy subjects, and possibly also in type 2 diabetic patients, by giving them a large meal, compared with a small meal, and its dependence on the magnitude of the meal stimulus is investigated. Expand
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
TLDR
Lack of GIP amplification of the late phase insulin response to glucose, which contrasts markedly to the normalising effect of GLP-1, could be a key defect in insulin secretion in Type II diabetic patients. Expand
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
TLDR
It is concluded that 48-h continuous subcutaneous infusion of GLP-1 in type 2 diabetic patients lowers fasting as well as meal-related plasma glucose, reduces appetite, has no gastrointestinal side effects, and has no negative effect on blood pressure. Expand
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
TLDR
It is concluded that during normal physiological plasma glucose levels, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide contribute nearly equally to the incretin effect in humans, because their differences in concentration and potency outweigh each other. Expand
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
TLDR
Near-normalisation of blood glucose for 4 weeks improves beta cell responsiveness to both GLP-1 and GIP by a factor of three to four, and no effect was found on betacell responsiveness to glucose alone. Expand
...
1
2
3
4
5
...